Mesothelioma Cancer Centers

The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) is a National Cancer Institute designated comprehensive cancer center. The center has maintained this designation since 1976. The more than 300 cancer researchers at the center provide individualized care for all cancer patients treated at the OSUCCC – James.

The OSUCCC – James leads the James Cancer Network, enabling patients to receive excellent care across the state of Ohio. Included in the network are the Wooster Community Hospital Health System, Madison County, Clinton Memorial Hospital and St. Rita’s Medical Center. The network elevates the care given across the state. The OSUCCC – James also offers cutting edge pediatric cancer care through the Nationwide Children’s Hospital (NCH).

Mesothelioma care offered at OSUCCC – James uses the most innovative treatment modalities offered across the United States. The physicians at the cancer center use standard therapies, like chemotherapy, radiation and surgery, as well as less accessible and more complicated therapies including monoclonal antibody therapy and other immunotherapies through clinical trials. The center is particularly experienced in treating peritoneal mesothelioma, offering specialized treatments like hyperthermic intraperitoneal chemotherapy (HIPEC).The multidisciplinary teams at OSUCCC – James provide patients with the best care possible to not only treat their cancer but also improve their overall quality of life.

Specializations:

• Chemotherapy
• Clinical trials
• Hyperthermic intraperitoneal chemotherapy (HIPEC)
• Immunotherapy
• Intensity-modulated radiation therapy
• Medical oncology
• Mesothelioma
• Monoclonal antibody therap
• Pleural mesotheliom
• Peritoneal mesothelioma
• Radiation oncology
• Surgical oncology
• Thoracic surgeons

Accreditations:

• American College of Surgeons Commission on Cancer (CoC) Accreditation
• Cancer Center ranked as High Performing according to U.S. News & World Report Best Hospitals report
• Foundation for the Accreditation of Cellular Therapy
• Member of the National Comprehensive Cancer Network (NCCN)
• National Cancer Institute (NCI) Designated Comprehensive Cancer Center
• The Joint Commission Accreditation

Mesothelioma Clinical Trials at The Ohio State University Comprehensive Cancer Center

The following clinical trials are in progress or actively recruiting participants at The Ohio State University Comprehensive Cancer Center:

• Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

  Conditions:	Acinar Cell Carcinoma; Adenoid Cystic Carcinoma; Adrenal Cortex Carcinoma; Adrenal Gland Pheochromocytoma; Anal Canal Neuroendocrine Carcinoma; Anal Canal Undifferentiated Carcinoma; Angiosarcoma; Apocrine Neoplasm; Appendix Mucinous Adenocarcinoma; Bartholin Gland Transitional Cell Carcinoma; Basal Cell Carcinoma; Bladder Adenocarcinoma; Cervical Adenocarcinoma; Cervical Clear Cell Adenocarcinoma; Cholangiocarcinoma; Chordoma; Colorectal Squamous Cell Carcinoma; Desmoid-Type Fibromatosis; Endometrial Transitional Cell Carcinoma; Endometrioid Adenocarcinoma; Esophageal Neuroendocrine Carcinoma; Esophageal Undifferentiated Carcinoma; Extrahepatic Bile Duct Carcinoma; Extramammary Paget Disease; Fallopian Tube Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fibromyxoid Tumor; Gallbladder Carcinoma; Gastric Neuroendocrine Carcinoma; Gastric Squamous Cell Carcinoma; Gastric Undifferentiated Carcinoma; Gastrointestinal Stromal Tumor; Gestational Trophoblastic Tumor; Giant Cell Carcinoma; Intestinal Neuroendocrine Carcinoma; Intrahepatic Cholangiocarcinoma; Lung Carcinoid Tumor; Lung Sarcomatoid Carcinoma; Major Salivary Gland Carcinoma; Malignant Odontogenic Neoplasm; Malignant Peripheral Nerve Sheath Tumor; Malignant Testicular Sex Cord-Stromal Tumor; Metaplastic Breast Carcinoma; Metastatic Malignant Neoplasm of Unknown Primary; Minimally Invasive Lung Adenocarcinoma; Mixed Mesodermal (Mullerian) Tumor; Mucinous Adenocarcinoma; Mucinous Cystadenocarcinoma; Nasal Cavity Adenocarcinoma; Nasal Cavity Carcinoma; Nasopharyngeal Carcinoma; Nasopharyngeal Papillary Adenocarcinoma; Nasopharyngeal Undifferentiated Carcinoma; Oral Cavity Carcinoma; Oropharyngeal Undifferentiated Carcinoma; Ovarian Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Germ Cell Tumor; Ovarian Mucinous Adenocarcinoma; Ovarian Squamous Cell Carcinoma; Ovarian Transitional Cell Carcinoma; Pancreatic Acinar Cell Carcinoma; Pancreatic Neuroendocrine Carcinoma; Paraganglioma; Paranasal Sinus Adenocarcinoma; Paranasal Sinus Carcinoma; Parathyroid Gland Carcinoma; PEComa; Peritoneal Mesothelioma; Pituitary Gland Carcinoma; Placental Choriocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Pseudomyxoma Peritonei; Rare Disorder; Scrotal Squamous Cell Carcinoma; Seminal Vesicle Adenocarcinoma; Seminoma; Serous Cystadenocarcinoma; Small Intestinal Adenocarcinoma; Small Intestinal Squamous Cell Carcinoma; Solid Neoplasm; Spindle Cell Neoplasm; Squamous Cell Carcinoma of the Penis; Teratoma With Somatic-Type Malignancy; Testicular Non-Seminomatous Germ Cell Tumor; Thyroid Gland Carcinoma; Tracheal Carcinoma; Transitional Cell Carcinoma; Ureter Adenocarcinoma; Ureter Squamous Cell Carcinoma; Urethral Adenocarcinoma; Urethral Squamous Cell Carcinoma; Vaginal Adenocarcinoma; Vaginal Squamous Cell Carcinoma, Not Otherwise Specified; Vulvar Carcinoma
  Last Updated:	July 18, 2019
  Status:	Recruiting

• Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin

  Conditions:	Advanced Malignant Solid Neoplasm; Advanced Peritoneal Malignant Mesothelioma; Advanced Pleural Malignant Mesothelioma; Recurrent Peritoneal Malignant Mesothelioma; Recurrent Pleural Malignant Mesothelioma; Refractory Malignant Solid Neoplasm; Unresectable Solid Neoplasm
  Last Updated:	June 10, 2019
  Status:	Recruiting

Sources